

---

## ...BIBLIOGRAPHY...

- AB BIODISK Package Insert, AB BIODISK, Inc., Piscataway, NJ.
- Ahkee S, Srinath L, Ramirez J. Community-acquired pneumonia in the elderly: Association of mortality with lack of fever and leukocytosis. *South Med J* 1997; 90:296-298.
- American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy. *Am Rev Respir Dis* 1993;148: 1418-1426.
- Anderson RM. The pandemic of antibiotic resistance. *Nat Med* 1999;5:147-149.
- Armstrong EP, Langley PC. Disease management programs. *Am J Health Syst Pharm* 1996;53:53-58.
- Ashton L. Disease-state management: Opportunities for pharmacists through risk-sharing. Editorial supplement. *Pharmaguide to Hospital Medicine* 1997;10:5-8.
- Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Guidelines from the Infectious Disease Society of America. Community-acquired pneumonia in adults: Guidelines for management. *Clin Infect Dis* 1998;26:811-838.
- Bartlett JG, Hillman AL, Niederman MS, Schwartz S, for the Continuum of Care Consensus Conference Panel. Clinical and economic consensus on early intervention in community-acquired pneumonia. *Infect Dis Clin Pract* 1996;5(suppl 4):S179-S184.
- Bartlett JG, Mundy LM. Community-acquired pneumonia. *N Engl J Med* 1995;333:1618-1624.
- Cohen ML. Epidemiology of drug resistance: Implications for a post-antibiotic era. *Science* 1992; 257:1050-1055.
- Coley CM, Li YH, Medsger AR, et al. Preferences for home vs. hospital care among low-risk patients with community-acquired pneumonia. *Arch Intern Med* 1996;156:1565-1571.
- Cunha BA. Community-acquired pneumonia cost-effective antimicrobial therapy. *Postgrad Med* 1996;99: 109-122.
- Davis R, Bryson HM. Levofloxacin: A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. *Drugs* 1994;47:677-700.
- *Drug Topics® Red Book®* 1997. Cardinale V, ed. Montvale, NJ: Medical Economics Company;1997.
- Einarson TR, McGhan WF, Bootman JL. Decision analysis applied to pharmacy practice. *Am J Hosp Pharm* 1985;42:364-371.
- Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implication for therapy: A prospective multicenter study of 359 cases. *Medicine* 1990;69:307-316.
- Farr BM, Kaiser DL, Harrison BDW, Connolly CK. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. *Thorax* 1987;44:1031-1035.
- File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. *Antimicrob Agents Chemother* 1997;41:1965-1972.
- Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. *N Engl J Med* 1997;336:243-250.
- Fine MJ, Hough LJ, Medsger AR, et al. The hospital admission decision for patients with community-acquired pneumonia. Results from the pneumonia patient outcomes research team cohort study. *Arch Intern Med* 1997;157:36-44.
- Fine MJ, Smith CA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. *JAMA* 1996;275:134-141.
- Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. *Clin Pharmacokinet* 1997;32:101-119.
- Fogarty CM, Sullivan JG, Chattman MS, Williams RR, Kojak C, Rubin A. Once a day levofloxacin in the treatment of mild to moderate and severe CAP in adults. *Infect Dis Clin Pract* 1998;7:400-407.
- Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults: Incidence, etiology, and impact. *Am J Med* 1985;78:S32-S37.
- Garrelts JC, Herrington AM. Cost-effective treatment of lower respiratory tract infections. *Pharmacoeconomics* 1996;10:36-58.

---

...BIBLIOGRAPHY...

- Gilbert K, Gleason PP, Singer DE, et al. Variations in antimicrobial use and cost in more than 2,000 patients with community-acquired pneumonia. *Am J Med* 1998;104:17-27.
- Ginesu F, Pirina P, Deiola G, Ostera S, Mele S, Fois AG. Etiology and therapy of community-acquired pneumonia. *J Chemother* 1997;9:285-292.
- Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. *JAMA* 1997;278:901-904.
- Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: Implications for practice guidelines. *JAMA* 1998;279:1452-1457.
- Hayakawa I, Furuhashi K, Takayama S, Osada Y. Levofloxacin, a new quinolone antibacterial agent. *Arzneim Forsch Drug Res* 1992;42:363-364.
- Henning JM. The role of clinical practice guidelines in disease management. *Am J Manag Care* 1998;4:1715-1724.
- Horn SD, Sharkey PD, Tracy DM, Horn CE, James B, Goodwin F. Intended and unintended consequences of HMO cost-containment strategies: Results from the Managed Care Outcomes Project. *Am J Manag Care* 1996;2:253-264.
- Huber S. Focus on levofloxacin, a broad-spectrum fluoroquinolone antimicrobial agent. *P&T* April 1998:173-182.
- Janssens JP, Gauthey L, Herrman F, et al. Community-acquired pneumonia in older patients. *J Am Geriatr Soc* 1996;44:539-544.
- Jones RN, Wilson WR. Epidemiology, laboratory detection, and therapy of penicillin-resistant streptococcal infections. *Diagn Microbiol Infect Dis* 1998;31:453-459.
- Kawai T. Clinical evaluation of levofloxacin 200 mg 3 times daily in the treatment of bacterial lower respiratory tract infections. *Drugs* 1995;49(suppl 2):416-417.
- King De, Pippin HJ Jr. Community-acquired pneumonia in adults: Initial antibiotic therapy. *Am Fam Physician* 1997;56:544-550.
- Klugman KP, Feldman C. The clinical relevance of antibiotic resistance in the management of pneumococcal pneumonia. *Infect Dis Clin Pract* 1998;7:180-184.
- Kristinsson KG. Effect of antimicrobial use and other risk factors on antimicrobial resistance in pneumococci. *Microbial Drug Resist* 1997;3:117-123.
- Lee LJ, Sha X, Gotfried MH, et al. Penetration of levofloxacin into lung tissue after oral administration to subjects undergoing lung biopsy or lobectomy. *Pharmacotherapy* 1998;18:35-41.
- Leroy O, Vandenbussche C, Coffinier C, et al. Community-acquired aspiration pneumonia in intensive care units. Epidemiologic and prognostic data. *Am J Respir Crit Care Med* 1997;156:1922-1929.
- Lynch JP, Martinez FJ. Community-acquired pneumonia. *Curr Opin Pulmonary Med* 1998;4:162-172.
- MacFarlane J. An overview of community-acquired pneumonia with lessons learned from the British Thoracic Society study. *Semin Respir Dis* 1994;9:153-165.
- MacFarlane JT, Miller AC, Smith WHR, et al. Comparative radiographic features of community-acquired Legionnaire's disease, pneumococcal pneumonia, Mycoplasma pneumoniae, and psittacosis. *Thorax* 1984;39:28-33.
- Markowitz JS, Pashko S, Gutterman EM, et al. Death rates among patients hospitalized with community-acquired pneumonia: A reexamination with data from three states. *Am J Public Health* 1996;86:1152-1154.
- Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: A 5-year prospective study. *Rev Infect Dis* 1989;11:586-599.
- Marrie TJ, Peeling RW, Fine MJ, et al. Ambulatory patients with community-acquired pneumonia: The frequency of atypical agents and clinical course. *Am J Med* 1996;101:508-515.
- Marston BJ, Plouffe JF, File TM Jr. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. *Arch Intern Med* 1997;157:1709-1718.
- Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process and outcome in elderly patients with pneumonia. *JAMA* 1997;278:2080-2084.
- Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. *Arch Intern Med* 1997;157:1453-1459.

---

...BIBLIOGRAPHY...

- Minogue MF, Coley CM, Fine MJ, et al. Patients hospitalized after initial outpatient treatment for community-acquired pneumonia. *Ann Emerg Med* 1998;31:376-380.
- Musher DM. Infections caused by *Streptococcus pneumoniae*: Clinical spectrum, pathogenesis, immunity, and treatment. *Clin Infect Dis* 1992;14:801-809.
- Musher DM. *Streptococcus pneumoniae*. In: Mandell GL, ed. *Principles and Practice of Infectious Diseases*. 4th ed. New York: Churchill Livingstone; 1995:1811-1823.
- Nakamori Y, Miyashita Y, Nakatani I, Nakatu K. Levofloxacin: Penetration into sputum and once-daily treatment of respiratory tract infections. *Drugs* 1995;49(suppl 2):418-419.
- National Committee for Clinical Laboratory Standards 1998. Performance Standards for Antimicrobial Susceptibility Testing: 8th Informational Supplement. Approved standard document M100-S8. National Committee for Clinical Laboratory Standards, Villanova, PA.
- Neu HC. The crisis in antibiotic resistance. *Science* 1992;257:1064-1072.
- Niederman MS, Bass JB, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy. Proceedings of an American Thoracic Society Consensus Conference. *Am Rev Respir Dis* 1993;148:1418-1426.
- Nuorti JP, Butler JC, Crutcher JM, et al. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. *N Engl J Med* 1998;26:1861-1868.
- Nyquist AC, Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis. *JAMA* 1998;279:875-877.
- Ortvist A. Initial investigation and treatment of the patient with severe community-acquired pneumonia. *Semin Respir Dis* 1994;9:66-79.
- Pareja A, Bernal C, Leyva A, Perdrola G, Maroto C. Etiologic study of patients with community-acquired pneumonia. *Chest* 1992;101(5):1207-1210.
- Pauker SJ, Kassirer JP. Decision analysis. *N Engl J Med* 1987;216:250-258.
- Porath A, Schlaeffer F, Lieberman D. Appropriateness of hospitalization of patients with community-acquired pneumonia. *Ann Emerg Med* 1996;27:176-183.
- Porath A, Schlaeffer F, Lieberman D. The epidemiology of community-acquired pneumonia among hospitalized adults. *J Infect* 1997;34:41-48.
- Przybelski K, Rybak M, Martin P, et al. A pharmacist-initiated program of intravenous to oral antibiotic conversion. *Pharmacotherapy* 1997;17:271-276.
- Ramirez J, Vargas J, Bordon J, Ahkee S. Clinical outcome of hospitalized patients with community-acquired pneumonia when the switch from IV to oral antibiotics is performed at the point of clinical stability. *Clin Infect Dis* 1997;25:425.
- Ramirez JA. Switch therapy in community-acquired pneumonia. *Diagn Microbiol Infect Dis* 1995;22:219-223.
- Reichler MR, Allphin AA, Breiman RF, et al. The spread of multiple resistant *Streptococcus pneumoniae* at a day care center in Ohio. *J Infect Dis* 1992;166:1346-1353.
- Report of the ASM Task Force on Antibiotic Resistance. American Society for Microbiology. *Antimicrob Agents Chemother* 1995;39(suppl):2-23.
- Richerson MA, Ambrose PG, Quintiliani R, et al. Pharmacoeconomic evaluation of alternative antibiotic regimens in hospitalized patients with community-acquired pneumonia. *Infect Dis Clin Pract* 1998;7:227-233.
- Riquelme R, Torres A, el-Ebiary M, et al. Community-acquired pneumonia in the elderly. Clinical and nutritional aspects. *Am J Respir Crit Care Med* 1997;156:1908-1914.
- Riquelme R, Torres A, el-Ebiary M, et al. Community-acquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors. *Am J Respir Crit Care Med* 1996;154:1450-1455.
- Rockefeller University Workshop. Special Report. Multiple-antibiotic resistant pathogenic bacteria. *N Engl J Med* 1994;330:1247-1251.
- Rubins JB, Janoff EN. Community-acquired pneumonia. Tailoring management of adult patients according to risk category. *Postgrad Med* 1997;102:45-62.
- Sato A, Ogawa H, Iwata M, et al. Clinical efficacy of levofloxacin in elderly patients with respiratory tract infections. *Drugs* 1995;49(suppl 2):428-429.

---

...BIBLIOGRAPHY...

- Schentag JJ. The pharmacoeconomics of treating hospital-acquired pneumonia: Developing a rational strategy. *Pharmaguide to Hosp Med* 1997;10:1-4,9-12.
- Shishido H, Furukawa K, Nagai H, Kawakami K, Kono H. Oral levofloxacin 600 mg and 300 mg daily doses in difficult-to-treat respiratory infections. *Drugs* 1995;49(suppl 2):433-435.
- Siegel RE, Halpern NA, Almenoff PL, Lee A, Cashin R, Greene JG. A prospective randomized study of inpatient intravenous antibiotics for community-acquired pneumonia: The optimal duration of therapy. *Chest* 1996;105:1109-1115.
- Siegel RE, Halpern NA, Almenoff PL, Lee A, Cashin R, Greene JG. A prospective randomized study of inpatient IV antibiotics for community-acquired pneumonia. *Chest* 1996;110:965-971.
- Swartz MN. Use of antimicrobial agents and drug resistance. *N Engl J Med* 1997;337:491-492.
- Tenover FC, Hughes JM. The challenges of emerging infectious diseases: Development and spread of multiple-resistant bacterial pathogens. *JAMA* 1996;275:300-304.
- Thornsberry C, Hickey ML, Diakun DR, et al. Surveillance of antimicrobial resistance among respiratory tract pathogens in the United States, 1997-1998. In: *Abstracts of the 38th ICAAC*; [abstract E22] 1998.
- Thornsberry C, Ogilvie P, Kahn J, et al. Surveillance of antimicrobial resistance in *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis* in the United States in 1996-1997 respiratory season. *Diagn Microbiol Infect Dis* 1997;29:249-257.
- US Department of Commerce, Bureau of the Census. Statistical abstract of the United States. 104th ed. Washington, DC: USGPO; 1984.
- White AC Jr, Atmar RL, Wilson J, et al. Effects of requiring prior authorization for selected antimicrobials: Expenditures, susceptibilities, and clinical outcomes. *Clin Infect Dis* 1997;25:230-239.
- Woodhead MA, MacFarlane JT. Comparative clinical laboratory features on *Legionella* with pneumococcal and *Mycoplasma pneumoniae*. *Br J Dis Chest* 1987; 81:133-139.